by Halima Namatovu, Wendy Hsu, Ruta Waghmare, Suneeta Wastler, Christi McDowell, and Bryan T. Butman
Volume 5, Issue 3 (Fall 2006)
Adenoviral vectors (AAV’s) offer a promising new approach to vaccine development. They have the ability to be rapidly manipulated for bearing transgenic coding for specific antigenic proteins, efficiently infect a variety of mammalian cell types (including antigen-presenting cells) and induce a broad immune response against the target antigen in vaccine recipients. Furthermore, AAV’s offer an excellent safety profile, in that they can be engineered to be non-replicating in the vaccine recipient and they lack the molecular mechanism for integration into the host genome. AAV’s are highly amenable to scalable manufacturing processes such as the use of stirred tank bioreactors, high capacity filtration methods, and chromatographic purification procedures…
Citation:
Namatovu H, Hsu W, Waghmare R, Wastler S, McDowell C, Butman BT. Evaluation of Filtration Products in the Production of Adenovirus Candidates Used in Vaccine Production: Overview and Case Study. BioProcess J, 2006; 5(3): 67-74. https://doi.org/10.12665/J53.Namatovu